CARCINOMA, RENAL CELL
Clinical trials for CARCINOMA, RENAL CELL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, RENAL CELL trials appear
Sign up with your email to follow new studies for CARCINOMA, RENAL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo for kidney cancer shows promise but trial halted early
Disease control TerminatedThis phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) helps people with advanced kidney cancer whose disease worsened after prior immunotherapy. The trial enrolled 522 participants but was terminated early, so the full benef…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental kidney cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cancer drug QEQ278 tested in Early-Stage trial
Disease control TerminatedThis early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control TerminatedThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Kidney cancer combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC